Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension

Schuster, Cornelia; Eikesdal, Hans P.; Puntervoll, Hanne; Geisler, Jürgen; Geisle, Stephanie; Heinrich, Daniel; Molven, Anders; Lønning, Per E.; Akslen, Lars A.; Straume, Oddbjørn
June 2012
PLoS ONE;Jun2012, Vol. 7 Issue 6, p1
Academic Journal
Background: VEGF driven angiogenesis plays a key role in cancer progression. We determined the clinical efficacy of bevacizumab monotherapy in patients with metastatic melanoma. Methods and Findings: Thirty-five patients with metastatic melanoma in progression were enrolled in this phase II, single arm clinical trial. Each patient received bevacizumab monotherapy 10 mg/kg q14 d until intolerable toxicity or disease progression occurred. Clinical efficacy was evaluated as objective response, disease control (DC), and survival. We observed one complete (3%) and 5 partial (14%) responses. In addition, 5 patients experienced stable disease >6 months (14%) while 24 patients had progressive disease (PD, 69%), corresponding to a total DC at 6 months in 11 out of 35 patients (31%). Median progression free survival (PFS) was 2.14 months and median overall survival (OS) was 9 months (1.12-49). Seven of the 11 patients experiencing DC developed early hypertension (<2 months) compared to 3/24 of patients with PD (P = 0.001), and hypertension was associated with PFS (P = 0.005) and OS (P = 0.013). Conclusion: Bevacizumab monotherapy demonstrated promising clinical efficacy in patients with metastatic melanoma with disease control in 31% of the patients. Induced early hypertension was a marker for clinical efficacy of bevacizumab.


Related Articles

  • Systemic Adverse Events after Intravitreal Bevacizumab versus Ranibizumab for Age-Related Macular Degeneration: A Meta-Analysis. Wang, Wei; Zhang, Xiulan // PLoS ONE;Oct2014, Vol. 9 Issue 10, p1 

    Objective: To assess whether the incidence of systemic adverse events differs between those who used bevacizumab and those who used ranibizumab in the treatment of age-related macular degeneration (AMD). Methods: A systematic literature search was conducted to identify randomised controlled...

  • A Phase 3 Trial of Bevacizumab in Ovarian Cancer. Perren, Timothy J.; Swart, Ann Marie; Pfisterer, Jacobus; Ledermann, Jonathan A.; Pujade-Lauraine, Eric; Kristensen, Gunnar; Carey, Mark S.; Beale, Philip; Cervantes, Andr�s; Kurzeder, Christian; Bois, Andreas du; Sehouli, Jalid; Kimmig, Rainer; St�hle, Anne; Collinson, Fiona; Essapen, Sharadah; Gourley, Charlie; Lortholary, Alain; Selle, Fr�d�ric; Mirza, Mansoor R. // New England Journal of Medicine;12/29/2011, Vol. 365 Issue 26, p2484 

    Background: Angiogenesis plays a role in the biology of ovarian cancer. We examined the effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women with this disease. Methods: We randomly assigned women with ovarian cancer to carboplatin (area under the curve, 5...

  • Peritumoral Apparent Diffusion Coefficient as a Metric of Response in Patients with Recurrent Glioblastoma Multiforme Treated with Bevacizumab and Irinotecan. Andre, J. B.; Lu, S.; Spearman, K.; Raval, S. N. // Neuroradiology Journal;Jun2008, Vol. 21 Issue 3, p350 

    Bevacizumab and irinotecan have shown promising results in patients with recurrent glioblastoma multiforme (GBM), which traditionally carries a poor prognosis after first-line therapies have been exhausted. Retrospectively documenting the short-term effects of this chemotherapeutic regimen on...

  • The effect of intravitreal bevacizumab and ranibizumab on macular edema of the contralateral eye: A comparative study of two anti-VEGFs. Bakbak, Berker; Ozturk, Banu Turgut; Gonul, Saban; Gedik, Sansal // Oman Journal of Ophthalmology;Jan-Apr2016, Vol. 9 Issue 1, p44 

    Purpose: To compare the effects of bevacizumab and ranibizumab on the visual function and macular thickness in the contralateral (untreated) eye of patients with bilateral diabetic macular edema (DME). Materials and Methods: Thirty-nine patients with bilateral DME, who had been treated with both...

  • A matched-control comparison of serious adverse events after intravitreal injections of bevacizumab for age-related macular degeneration and cataract extraction. Fischer, Naomi; Moisseiev, Elad; Waisbourd, Michael; Goldstein, Michaella; Loewenstein, Anat // Clinical Ophthalmology;2013, Vol. 7, p621 

    Purpose: The study reported here investigated the rates of systemic serious adverse events (SAEs) following treatment with intravitreal bevacizumab for age-related macular degeneration (AMD) in comparison with a matched control group. Methods: A retrospective age- and sex-matched case-control...

  • Global comparative trials of anti-VEGFs continue to teach lessons.  // Ocular Surgery News;2/25/2014, Vol. 32 Issue 4, p30 

    The article reports that no significant difference between bevacizumab and ranibizumab is found in terms of systemic serious adverse events after two years of study based on six published trials according to ophthalmologist Dr. Daniel F. Martin.

  • Off with the label and on the Avastin bandwagon: Why now and how far? Gopal, K. S. Santhan // Indian Journal of Ophthalmology;Sep2009, Vol. 57 Issue 4, p253 

    The article presents the author's views about the "off label" use of avastin by ophthalmologists. The author says that the ophthalmologist must be aware of the legal, financial, industrial and ethical implications of its use. The author further says that avastin certainly looks the best option...

  • Investigational Angiogenesis Inhibitor Ramucirumab Improves Survival as Second-Line Treatment. Kuznar, Wayne // Oncology Pharmacist;May2014, Vol. 7 Issue 2, p19 

    No abstract available.

  • Ranibizumab.  // Reactions Weekly;Apr2015, Vol. 1546 Issue 1, p177 

    The article presents case reports of three patients who developed endophthalmitis during treatment with ranibizumab for neovascular age-related macular degeneration. It is noted that prior to intravitreal injection (IVI), a periocular scrub using povidone/iodine (PVI) was performed and PVI drops...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics